Direct comparison
Biotech vs Standard Tech Licensing Deals
Biotech/pharma licenses add milestone payments, royalty-stacking clauses, and field-of-use limits rarely used in standard tech licensing deals.
Written and maintained by CASRAI Editorial Board
Last updated
Ask CASRAI · included with Regulatory Radar
Ask about Biotech vs Standard Tech Licensing Deals
Ask CASRAI answers research-administration questions and cites the passages behind every claim — and says so when the corpus does not cover something, instead of guessing. It comes with a Regulatory Radar subscription at $29 a month, alongside the daily digest of regulatory changes and the dashboard of what changed.
150 questions a day, on this site, over the API, or inside your own tools through the CASRAI MCP server.
Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays free to read, with no account and no card.
How do Biotech/Pharma Licensing, Standard Tech Licensing compare side by side?
The table below compares Biotech/Pharma Licensing, Standard Tech Licensing across 9 procurement-relevant dimensions, from typical licensed asset through sublicensing terms.
Side-by-side comparison
| Dimension | Biotech/Pharma Licensing | Standard Tech Licensing |
|---|---|---|
| Typical licensed asset | Drug candidate, biologic, diagnostic, platform technology | Software, engineering process, hardware component, materials patent |
| Path to revenue | Long (often 10+ years): preclinical, multi-phase clinical trials, regulatory approval | Short to moderate; often near-market or requires only incremental development |
| Milestone payments | Standard practice -- staged development/regulatory milestones (IND filing, trial phases, approval) plus commercial sales milestones | Uncommon -- often a single upfront fee and/or running royalty, few or no staged milestones |
| Royalty stacking provisions | Common -- anti-stacking (royalty-offset) clauses and/or stacking caps, since one product often embeds several independently licensed IP rights | Rare -- fewer independently licensed inputs typically stack into one product |
| Field-of-use restrictions | Heavily used -- licenses commonly split by therapeutic area/indication, with field-by-field royalty terms | Used, but less central -- broader or simpler field grants are more typical |
| Diligence/development obligations | Near-universal -- spend commitments, IND/trial-initiation deadlines, reversion or march-in rights if licensee stalls | Used inconsistently -- shorter, lower-risk commercialization path reduces the need |
| Typical deal timeline to close | Often many months, given milestone-schedule and royalty-stacking complexity | Weeks to a few months |
| Equity as consideration | Common, especially licensing to a cash-constrained university spinout | Less common outside of startup-specific deals |
| Sublicensing terms | Typically requires licensor consent plus a defined sublicense-revenue share | Allowed, but revenue-share mechanics are often simpler |
Common questions
Common questions about Biotech/Pharma Licensing vs Standard Tech Licensing
Do all biotech licenses include milestone payments?
+
Not universally, but staged development, regulatory, and commercial milestone payments are the dominant structure for licensing a pre-revenue drug candidate, biologic, or platform technology -- they let the licensor share in risk-adjusted value at each stage rather than pricing the whole deal as a single upfront transaction.
What is an anti-stacking provision?
+
A contract clause letting the licensee reduce the royalty owed to one licensor by a percentage of royalties it separately owes to other licensors for additional IP necessary to make, use, or sell the same product -- usually subject to a floor below which the royalty cannot drop. It exists to keep a product commercially viable when it embeds multiple independently licensed inputs.
Why does field-of-use matter more in biotech licensing?
+
A single platform technology or composition of matter often has legitimate, non-competing uses across multiple therapeutic areas (oncology, immunology, diagnostics, veterinary use). Splitting the license by field lets a licensor monetize the same invention across several non-competing licensees instead of granting one party blanket rights it will only use in one indication.
Can a standard technology license use milestone payments too?
+
Yes -- nothing prevents it structurally. It is simply less common, because most standard technology assets have a shorter, more predictable path to market that does not require staging payments across a decade-long, high-attrition development process the way a drug candidate does.
